logo
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

Globe and Mail4 days ago
Key Points
Exelixis' most important product should continue driving strong financial results through the end of the decade.
The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel.
The midcap biotech looks well-positioned to deliver market-beating returns over the long run.
10 stocks we like better than Exelixis ›
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015.
Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank.
EXEL Total Return Level data by YCharts.
Cabometyx is still doing the heavy lifting
Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment).
Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62.
Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets.
Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality.
The next stage of growth
Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC).
Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options.
Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages.
Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care.
As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate.
Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition.
Can Exelixis get to $200?
From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates.
Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy.
Should you invest $1,000 in Exelixis right now?
Before you buy stock in Exelixis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

S&P/TSX composite ticks higher Thursday
S&P/TSX composite ticks higher Thursday

CTV News

time7 minutes ago

  • CTV News

S&P/TSX composite ticks higher Thursday

The TMX Market Centre is shown in Toronto, Wednesday, Sept. 11, 2024. THE CANADIAN PRESS/Paige Taylor White TORONTO — Gains in energy stocks helped Canada's main stock index tick higher in late-morning trading on Thursday, while U.S. markets were mixed. The S&P/TSX composite index was up 4.21 points at 27,420.62. In New York, the Dow Jones industrial average was down 129.58 points at 44,880.71. The S&P 500 index was up 17.18 points at 6,376.09, while the Nasdaq composite was up 56.71 points at 21,076.73. The Canadian dollar traded for 73.38 cents US compared with 73.48 cents US on Wednesday. The September crude oil contract was up US$1.08 at US$66.33 per barrel. The August gold contract was down US$22.00 at US$3,375.60 an ounce. This report by The Canadian Press was first published July 24, 2025.

Why American Airlines Stock Tumbled Today
Why American Airlines Stock Tumbled Today

Globe and Mail

time25 minutes ago

  • Globe and Mail

Why American Airlines Stock Tumbled Today

Key Points American Airlines beat on sales and earnings this morning. Revenues held steady year over year, but profits declined 10%. American Airlines says it will lose money in Q3, and could lose money for the full year as well. 10 stocks we like better than American Airlines Group › American Airlines (NASDAQ: AAL) stock sank 7.2% through 10:55 a.m. ET Thursday despite reporting an earnings beat for Q2 this morning. Analysts forecast the airline company would earn $0.77, adjusted for one-time items, on $14.3 billion in Q2 sales. In fact, the airline earned $0.95 on sales of $14.4 billion. American Airlines Q2 earnings What's bad about that? Combing through the numbers, here's what we find: Earnings as calculated according to generally accepted accounting principles (GAAP) were lower than the adjusted figure of $0.91. This was down 10% from what AA earned a year ago, despite quarterly revenue remaining roughly flat. So obviously, profit margins declined. But why? Well, fuel costs were lower in Q2 2025 than a year ago, but salaries, wages, and benefits cost 11% more, and landing fees grew 7%. Those were among the biggest changes that stand out. Is American Airlines stock a sell? I doubt these costs are what's upset investors today, however. Looming larger are concerns about "macro weaknesses" in the economy that are affecting company guidance. Although American Airlines management says it doesn't necessarily see a reason to worry right now, it worries anyway -- and after reporting its big Q2 profit, told investors it might lose as much as $0.60 per share in Q3, while full-year results could be as good as a $0.80 per-share profit... or as bad as a $0.20 per-share loss. That's a pretty wide range of potential outcomes for the year, and the only thing AA seems certain of is that it will definitely lose money in the current quarter. With a market cap of only $7.8 billion but more than $ 28 billion in debt and losses on the horizon, maybe investors should worry about AAL stock, too. Should you invest $1,000 in American Airlines Group right now? Before you buy stock in American Airlines Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and American Airlines Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025

ScalaHosting To Power California State University, Sacramento With Secure, Scalable, and High-Performance Cloud Infrastructure in New Partnership
ScalaHosting To Power California State University, Sacramento With Secure, Scalable, and High-Performance Cloud Infrastructure in New Partnership

Globe and Mail

time37 minutes ago

  • Globe and Mail

ScalaHosting To Power California State University, Sacramento With Secure, Scalable, and High-Performance Cloud Infrastructure in New Partnership

ScalaHosting's secure, scalable cloud hosting solutions will be integrated into CSUS's digital services to strengthen campus cybersecurity and infrastructure reliability. This new alliance will accelerate digital transformation in higher education. ScalaHosting, a global leader in managed cloud VPS hosting solutions, is proud to announce a multifaceted strategic partnership with California State University, Sacramento (Sac State), one of the largest public universities in California and a recognized leader in academic excellence and innovation. Through this alliance, ScalaHosting will integrate its scalable, secure cloud hosting solutions across CSUS's digital services ecosystem to strengthen its cybersecurity and enhance the performance and reliability of its infrastructure. With growing demand for educational institutions to provide always-on access to online platforms, CSUS is demonstrating its forward-thinking approach to digital infrastructure through this partnership. As one of the most respected institutions in the California State University system, the university plays a pivotal role in shaping the academic and digital experiences of thousands of learners each year. This decision to move to ScalaHosting marks a significant milestone, reinforcing the institution's dedication to delivering web hosting solutions that meet the high standards and expectations of enterprise-level organizations and public institutions. At the same time, this move underscores the university's commitment to security, performance, and long-term scalability as it supports its thousands of students, faculty, and staff. ScalaHosting brings to this partnership its enterprise-grade reliability, ironclad security, lighting fast servers, 24/7 support, and managed VPS cloud hosting. The cloud solutions provider also offers access to cutting-edge tools like Spanel, a control panel designed to reduce complexity and boost control, enabling institutions to streamline their server management without sacrificing flexibility or compliance. In accordance with the partnership, CSUS has initiated the migration of its key websites, including its Moodle LMS websites, to ScalaHosting's cutting-edge Cloud VPS platform. Chris Rusev, the CEO and co-founder of ScalaHosting and expressed his excitement about this partnership, calling it an opportunity for ScalaHosting to flex its cloud hosting and management capabilities and demonstrate how educational institutions can future-proof their digital transformation with next-generation hosting solutions. 'We are excited and honored to support CSUS in its mission to provide secure, scalable, and high-availability services for its learners, staff and faculty. CSUS's trust in us reaffirms our ability to accelerate digital transformation for higher learning by helping institutions manage their key digital resources that support course delivery and academic operations.' This strategic partnership also highlights ScalaHosting's commitment to delivering high-performance hosting environments tailored to various sectors, including education, government, and enterprise. California State University, Sacramento, joins a growing list of organizations turning to ScalaHosting to upgrade their cybersecurity and digital infrastructure with managed cloud hosting. About ScalaHosting: ScalaHosting is a U.S.-based cloud solutions provider trusted by over 1,000,000 websites worldwide. With a focus on innovation, security, and service, ScalaHosting offers fully managed cloud VPS, dedicated servers, and cutting-edge tools like SPanel, the next-generation web hosting control panel. For more information, please visit Media Contact Company Name: ScalaHosting Contact Person: Chris Rusev Email: Send Email Phone: 214 306 6818 Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store